Severe cutaneous adverse reactions to drugs (SCAR): Definitions, diagnostic criteria, genetic predisposition

Dermatologica Sinica

Volumn 27, Issue 4, 2009, Pages 203-209

  Roujeau, Jean Claude ^a,b   Allanore, Laurence ^a,b   Liss, Yvonne ^b   Mockenhaupt, Maja ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adverse drug reactions; Drug hypersensitivity; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ALLOPURINOL; AMINOPENICILLIN; CARBAMAZEPINE; CHLOROQUINE; DAPSONE; DILTIAZEM; GOLD SALT; HLA B ANTIGEN; HYDROXYCHLOROQUINE; LAMOTRIGINE; MINOCYCLINE; PHENOBARBITAL; PHENYTOIN; PRISTINAMYCIN; SULFONAMIDE; TERBINAFINE;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; CLINICAL FEATURE; DRESS SYNDROME; EPIDERMOLYSIS; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; REVIEW; SKIN BIOPSY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 74549143149     PISSN: 10278117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Hunziker T, Kunzi UP, Braunschweig S, et al.: Comprehensive hospital drug monitoring (CH-DM): adverse skin reactions, a 20-year survey. Allergy 52: 388-393, 1997.
2. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N Eng J Med 331: 1272-1285, 1994.
3. Kelly JP, Auquier A, Rzany B, et al.: An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol 48: 1099-1108, 1995.
4. Beylot C, Bioulac P, Doutre MS: Pustulose exanthématique aigue généralisé e, 4 cas. Ann Dermatol Venereol 107: 37-48, 1980.
5. Sidoroff A, Halevy S, Bavinck JN, et al.: Acute generalized exanthematous pustulosis (AGEP) - a clinical reaction pattern. J Cutan Pathol 28: 113-119, 2001.
6. Sidoroff A, Dunant A, Viboud C et al.: Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational casecontrol study (EuroSCAR). Br J Dermatol 157: 989-996, 2007.
7. Britschgi M, Steiner UC, Schmid S, et al.: T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 107: 1433-1441, 2001.
8. Bocquet H, Bagot M, Roujeau JC: Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 15: 250-257, 1996.
9. Shiohara T, Inaoka M, Kano Y: drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpes-viruses and antiviral and antidrug immune responses. Allergol Int 55: 1-8, 2006.
10. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al.: Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 156: 609-611, 2007.
11. Peyriere H, Dereure O, Breton H, et al.: Variability in the clinical pattern of cutaneous side effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 155: 422-428, 2006.
12. Seishima M, Yamanaka S, Fujisawa T, et al.: Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol 155: 344-349, 2006.
13. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al.: SCAR Study Group. Severe Cutaneous Adverse Reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138: 1019-1024, 2002.
14. Ruiz-Maldonado R: Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol 13: 623-635, 1985.
15. Ting W, Stone MS, Racila D, et al.: Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for a new classification of lupus erythematosus vesiculobullous skin lesions. Lupus 13: 941-950, 2004.
16. Roujeau JC, Kelly JP, Naldi L, et al.: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333: 1600-1607, 1995.
17. Mockenhaupt M, Viboud C, Dunant A, et al.: Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128: 35-44, 2008.
18. Nassif A, Bensussan A, Boumsell L, et al.: Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 114: 1209-1215, 2004.
19. Chung WH, Hung SI, Yang JY, et al.: Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14: 1343-1350, 2008.
20. Schneck J, Fagot JP, Sekula P, et al.: Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 58: 33-40, 2008.
21. Chung WH, Hung SL, Hong HS, et al.: A marker for Stevens-Johnson syndrome. Nature 428: 486, 2004.
22. Hung SL Chung WH, Liou LB, et al.: HLAB*58-01 allele as a genetic marker for severe cutaneous reactions caused by allopurinol. Proc Natl Acad Sci USA 102: 4134, 2005.
23. Lonjou C, Thomas L, Borot N, et al.: RegiSCAR Group. A marker for Stevens-Johnson syndrome ...: ethnicity matters. Pharmacogenomics J 6: 265-268, 2006.
24. Lonjou C, Borot N, Sekula P, et al.: RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18: 99-107, 2008.